Magnetic Resonance Imaging Angiography of Physiological and Pathological Pregnancy Placentas Ex Vivo: Protocol for a Prospective Pilot Study.

IUGR MRI PE intrauterine intrauterine growth restriction magnetic resonance imaging pathology physiology placenta preeclampsia pregnancy uterine vasculogenesis

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
10 Aug 2022
Historique:
received: 01 12 2021
accepted: 27 04 2022
revised: 09 02 2022
entrez: 10 8 2022
pubmed: 11 8 2022
medline: 11 8 2022
Statut: epublish

Résumé

Preeclampsia (PE) and intrauterine growth restriction (IUGR) are 2 major pregnancy complications due to abnormal placental vasculogenesis. Data on whole fetoplacental vasculature are still missing; hence, these pathologies are not well understood. Ex vivo magnetic resonance imaging (MRI) angiography has been developed to characterize the human placental vasculature by injecting a contrast agent within the umbilical cord. The primary objective of this study is to compare the placental vascular architecture between normal and pathological pregnancies. This study's secondary objectives are to (1) compare texture features on MRI between groups (normal and pathological), (2) quantitatively compare the vascular architecture between both pathological groups (pathological IUGR, and pathological PE), (3) evaluate the quality of the histological examination in injected placentas, and (4) compare vascularization indices to histological characteristics. This is a prospective controlled study. We expect to include 100 placentas: 40 from normal pregnancies and 60 from pathological pregnancies (30 for IUGR and 30 for PE). Ex vivo MR image acquisition will be performed shortly after delivery and with preparation by injection of a contrast agent in the umbilical cord. The vascular architecture will be quantitatively described by vascularization indices measured from ex vivo MRI angiography data. Comparisons of vascularization indices and texture features in accordance with the group and within comparable gestational age will be also performed. After MR image acquisition, placental histopathological analysis will be performed. The enrollment of women began in November 2019. In view of the recruitment capacity of our institution and the availability of the MRI, recruitment should be completed by March 2022. As of November 2021, we enrolled 70% of the intended study population. This study protocol aims to provide information about the fetal side of placental vascular architecture in normal and pathological placenta through MRI. Clinicaltrials.gov NCT04389099; https://clinicaltrials.gov/ct2/show/NCT04389099. DERR1-10.2196/35051.

Sections du résumé

BACKGROUND BACKGROUND
Preeclampsia (PE) and intrauterine growth restriction (IUGR) are 2 major pregnancy complications due to abnormal placental vasculogenesis. Data on whole fetoplacental vasculature are still missing; hence, these pathologies are not well understood. Ex vivo magnetic resonance imaging (MRI) angiography has been developed to characterize the human placental vasculature by injecting a contrast agent within the umbilical cord.
OBJECTIVE OBJECTIVE
The primary objective of this study is to compare the placental vascular architecture between normal and pathological pregnancies. This study's secondary objectives are to (1) compare texture features on MRI between groups (normal and pathological), (2) quantitatively compare the vascular architecture between both pathological groups (pathological IUGR, and pathological PE), (3) evaluate the quality of the histological examination in injected placentas, and (4) compare vascularization indices to histological characteristics.
METHODS METHODS
This is a prospective controlled study. We expect to include 100 placentas: 40 from normal pregnancies and 60 from pathological pregnancies (30 for IUGR and 30 for PE). Ex vivo MR image acquisition will be performed shortly after delivery and with preparation by injection of a contrast agent in the umbilical cord. The vascular architecture will be quantitatively described by vascularization indices measured from ex vivo MRI angiography data. Comparisons of vascularization indices and texture features in accordance with the group and within comparable gestational age will be also performed. After MR image acquisition, placental histopathological analysis will be performed.
RESULTS RESULTS
The enrollment of women began in November 2019. In view of the recruitment capacity of our institution and the availability of the MRI, recruitment should be completed by March 2022. As of November 2021, we enrolled 70% of the intended study population.
CONCLUSIONS CONCLUSIONS
This study protocol aims to provide information about the fetal side of placental vascular architecture in normal and pathological placenta through MRI.
TRIAL REGISTRATION BACKGROUND
Clinicaltrials.gov NCT04389099; https://clinicaltrials.gov/ct2/show/NCT04389099.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
DERR1-10.2196/35051.

Identifiants

pubmed: 35947435
pii: v11i8e35051
doi: 10.2196/35051
pmc: PMC9403824
doi:

Banques de données

ClinicalTrials.gov
['NCT04389099']

Types de publication

Journal Article

Langues

eng

Pagination

e35051

Informations de copyright

©Matthieu Dap, Bailiang Chen, Claire Banasiak, Gabriela Hossu, Olivier Morel, Marine Beaumont, Charline Bertholdt. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 10.08.2022.

Références

Placenta. 2020 Nov;101:4-12
pubmed: 32905974
Obstet Gynecol Clin North Am. 2020 Mar;47(1):197-213
pubmed: 32008669
Tomography. 2019 Dec;5(4):333-338
pubmed: 31893231
Placenta. 2022 Jan;117:5-12
pubmed: 34768169
Am J Obstet Gynecol. 2018 Feb;218(2S):S745-S761
pubmed: 29422210
Placenta. 2017 Dec;60:36-39
pubmed: 29208237
BJOG. 2021 Jan;128(2):346
pubmed: 32772422
Eur J Obstet Gynecol Reprod Biol. 2015 Oct;193:10-8
pubmed: 26207980
Development. 2019 Nov 27;146(22):
pubmed: 31776138
Placenta. 2020 Nov;101:251
pubmed: 33092722
Med Image Anal. 2017 Jan;35:685-698
pubmed: 27788384
BMC Physiol. 2010 Mar 12;10:3
pubmed: 20226038
Methods Mol Biol. 2018;1710:173-189
pubmed: 29197003
APMIS. 2018 Jul;126(7):561-569
pubmed: 30129125
Lancet. 2015 May 30;385(9983):2162-72
pubmed: 25747582
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
BMJ Open. 2019 Sep 11;9(9):e030353
pubmed: 31511289
Placenta. 2019 Dec;88:36-43
pubmed: 31670095
Sci Rep. 2017 Jun 23;7(1):4144
pubmed: 28646147
Arch Pathol Lab Med. 2016 Jul;140(7):698-713
pubmed: 27223167
Placenta. 2017 Oct;58:40-45
pubmed: 28962694
APMIS. 2018 Jul;126(7):551-560
pubmed: 30129127
Magn Reson Med. 2019 Jan;81(1):350-361
pubmed: 30239036
Placenta. 2020 Jul;96:34-43
pubmed: 32560856

Auteurs

Matthieu Dap (M)

Obstetric and Fetal Medicine Unit, Centre Hospitalier Régional Universitaire of Nancy, Nancy, France.
Department of Foetopathology and Placental Pathology, Centre Hospitalier Régional Universitaire of Nancy, Nancy, France.

Bailiang Chen (B)

INSERM U1254, IADI, Vandoeuvre-lès-Nancy, France.
INSERM CIC-IT 1433 Innovative Technology, University of Lorraine and University Hospital of Nancy, Nancy, France.

Claire Banasiak (C)

INSERM CIC-IT 1433 Innovative Technology, University of Lorraine and University Hospital of Nancy, Nancy, France.

Gabriela Hossu (G)

INSERM CIC-IT 1433 Innovative Technology, University of Lorraine and University Hospital of Nancy, Nancy, France.

Olivier Morel (O)

Obstetric and Fetal Medicine Unit, Centre Hospitalier Régional Universitaire of Nancy, Nancy, France.
INSERM U1254, IADI, Vandoeuvre-lès-Nancy, France.

Marine Beaumont (M)

INSERM U1254, IADI, Vandoeuvre-lès-Nancy, France.
INSERM CIC-IT 1433 Innovative Technology, University of Lorraine and University Hospital of Nancy, Nancy, France.

Charline Bertholdt (C)

Obstetric and Fetal Medicine Unit, Centre Hospitalier Régional Universitaire of Nancy, Nancy, France.
INSERM U1254, IADI, Vandoeuvre-lès-Nancy, France.

Classifications MeSH